The European Union stands at an unprecedented crossroads in its technological trajectory. For over a decade, European policymakers have pioneered an ambitious, values driven framework aimed at establishing normative global standards for digital privacy, algorithmic transparency, platform contestability and fundamental human rights. Prominent pillars of this framework include the General Data Protection Regulation (GDPR), the Digital Markets Act (DMA), and the Artificial Intel

The European behavioural health technology ecosystem is undergoing a structural paradigm shift. The initial wave of digital mental health, dominated by general consumer wellness, unguided meditation apps, and simple direct to consumer therapy marketplaces, has given way to a clinical grade ecosystem. As public healthcare systems across Europe face chronic clinician shortages and mounting therapy waitlists, governments, enterprise employers and institutional insurers are deman

The rapid integration of artificial intelligence into clinical workflows has exposed a fundamental mismatch between traditional legal concepts of property and the realities of modern health data processing. As machine learning models, autonomous clinical agents, and natural language algorithms ingest electronic health records (EHRs), generate predictive risk scores, and synthesize novel patient profiles, a central jurisdictional conflict emerges regarding who legally owns thi

The rapid proliferation of glucagon-like peptide-1 (GLP-1) receptor agonists and multi-target incretin mimetics represents the most disruptive structural force in modern healthcare since the emergence of digital health itself. Originally developed for type 2 diabetes management, these pharmacological interventions, including semaglutide and dual GLP-1/GIP agonists like tirzepatide, have expanded into chronic weight management, cardiovascular risk reduction, and metabolic dy

The global longevity and healthy ageing sector sits at an unprecedented inflection point between fundamental biological innovation and consumer health commercialisation. Driven by demographic shifts that will see the population aged 80 and older reach 265 million by the mid-2030s, alongside a widening healthspan-lifespan gap currently estimated at ten years in developed markets, the sector has attracted intense institutional, corporate and private equity interest.

For over two decades, major technology conglomerates attempted to capture the business-to-consumer (B2C) personal health record (PHR) market, committing billions of dollars toward consumer-facing health repositories. Initiatives such as Microsoft HealthVault (2007–2019), Google Health (2008–2012), and Amazon’s healthcare endeavours, spanning Haven, Amazon Care, and the Halo wellness line—failed to achieve meaningful consumer penetration or long-term engagement.

Today, the digital health market stands at a critical juncture regarding whether platforms should own the complete, longitudinal care pathway or remain specialised point solutions. Institutional due diligence and corporate procurement trends indicate that the standalone point solution model is experiencing structural failure. Enterprise buyers are suffering from severe point solution fatigue, driven by administrative vendor bloat, depressed member engagement, disconnected pat

The financing of European medical technology is undergoing a structural transition that challenges the viability of its historical funding mechanisms. For decades, early-stage medtech innovation relied on the traditional venture capital model, which was originally pioneered to support the rapid scaling, high gross margins, and predictable, capital-efficient exit pathways of the software industry. However, the combination of physical hardware development timelines, complex and